Scalper1 News
Valeant Pharmaceuticals (VRX) is reportedly mulling a higher bid for Salix Pharmaceuticals (SLXP) even as Valeant investor Bill Ackman said it won’t “overpay.” Valeant is considering raising its all-cash offer to above $160 a share, according to multiple reports citing sources. It was originally reported Friday afternoon by New York Times. Valeant plans weekend meetings to discuss the issue, with no specific figure cited. Valeant last month agreed Scalper1 News
Scalper1 News